Zolmitriptan

Mechanism :

Selective agonist for serotonin (5-HT_1B and 5-HT_1D receptors) in cranial arteries and sensory nerves of the trigeminal system; causes vasoconstriction and reduces inflammation associated with antidromic neuronal transmission correlating with relief of migraine

Indication :

• Acute treatment of migraine in children >12 years

Contraindications :

Hypersensitivity to zolmitriptan or any component of the formulation; ischemic coronary artery disease. Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders; peripheral vascular disease; ischemic bowel disease; uncontrolled hypertension; recent use (within 24 hours) of treatment with another 5-HT₁ agonist, or an ergotamine-containing or ergot-type medication like dihydroergotamine or methysergide; history of stroke, transient ischemic attack, or history of hemiplegic or basilar migraine.

Dosing :

Adverse Effect :

Unpleasant taste, chest pain, facial edema, palpitations, cardiac arrhythmia, dizziness, paresthesia, drowsiness, diaphoresis, nausea, hypersensitivity reaction, local pain, application site irritation, weakness, nasal discomfort.

Interaction :

Ergot Derivatives: May enhance the vasoconstricting effect of Serotonin 5-HT1D Receptor Agonists. Serotonin 5-HT1D Receptor Agonists may enhance the vasoconstricting effect of Ergot Derivatives. Exceptions: Nicergoline.
Methylene Blue: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.
Monoamine Oxidase Inhibitors: May decrease the metabolism of Serotonin 5-HT1D Receptor Agonists. Management: If MAO inhibitor therapy is required, naratriptan, Eletriptan or frovatriptan may be a suitable 5-HT1D agonist to employ.
Sumatriptan: Serotonin 5-HT1D Receptor Agonists may enhance the adverse/toxic effect of Sumatriptan.

Renal Dose :

Hepatic Dose :